Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vosoritide in children with hypochondroplasia
NCT06455059Phase 3Active, not recruiting
- Sponsor
- BioMarin Pharmaceutical
- Start
- Jun 2024
- Primary completion
- Aug 2026
- Modality
- Peptides
- Countries
- 9
01
Overview
A Phase 3 trial of vosoritide in hypochondroplasia (HCH), sponsored by BioMarin Pharmaceutical. Started Jun 2024; status: active, not recruiting.
02
Drugs
vosoritide
03
Conditions
hypochondroplasia (HCH)
Beyond the preview
Go deeper on NCT06455059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06455059.